Jupiter Neurosciences files Prospectus Supplement May 21, 2026

Jupiter Neurosciences, Inc. filed a Prospectus Supplement No. 4 dated May 21, 2026 that updates and supplements the Prospectus dated December 11, 2025 by attaching its Current Report on Form 8-K filed with the SEC on May 21, 2026.

Rhea-AI Filing Summary

Jupiter Neurosciences, Inc. filed a Prospectus Supplement No. 4 dated May 21, 2026 that updates and supplements the Prospectus dated December 11, 2025 by attaching its Current Report on Form 8-K filed with the SEC on May 21, 2026. The supplement must be read together with the Prospectus and is qualified by reference to it.

Key Figures

Registration number: 333-291832 Prospectus supplement date: May 21, 2026 Prospectus date: December 11, 2025 +2 more

5 metrics

Registration number 333-291832 Form S-1 Registration No.

Prospectus supplement date May 21, 2026 date of this prospectus supplement

Prospectus date December 11, 2025 date of the Prospectus being supplemented

Closing price $0.2050 closing price per share on May 20, 2026

Par value $0.0001 per share par value of Common Stock

Key Terms

Prospectus Supplement, Registration Statement on Form S-1, Current Report on Form 8-K

3 terms

Prospectus Supplement regulatory

"This prospectus supplement updates, amends and supplements the prospectus dated December 11, 2025"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Registration Statement on Form S-1 regulatory

"which forms a part of our Registration Statement on Form S-1 (Registration No. 333-291832)"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

Current Report on Form 8-K regulatory

"attaching the Current Report to this prospectus supplement filed with the SEC on May 21, 2026"

A current report on Form 8-K is a document that publicly traded companies file to promptly share important news or events that could affect their financial position or stock price, such as major business changes or legal issues. It helps investors stay informed about timely developments, allowing them to make better decisions about buying or selling shares.

Offering Details

base_shelf_indeterminate

Offering

Offering Type base_shelf_indeterminate

Securities Offered common stock

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Jupiter Neurosciences (JUNS) prospectus supplement dated May 21, 2026 do?

The supplement updates the Prospectus dated December 11, 2025 by attaching the company’s Current Report on Form 8-K filed with the SEC on May 21, 2026 and amends information in the Prospectus accordingly.

Will the May 21, 2026 supplement change the original prospectus delivery?

The supplement must be read in conjunction with the Prospectus dated December 11, 2025 and is qualified by reference to it; the Prospectus continues to be delivered with this supplement.

What class of securities is referenced in this prospectus supplement for JUNS?

The supplement references the company’s Common Stock, par value $0.0001 per share, which is listed on Nasdaq under the symbol JUNS.

Does the supplement disclose a market price for JUNS common stock?

Yes. The document states the closing price of Common Stock on May 20, 2026 was $0.2050 per share.

Has the SEC approved the securities described in the supplement?

No. The supplement states that neither the SEC nor any state securities commission has approved or disapproved the securities or determined if the Prospectus or supplement is truthful or complete.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 09:54 AM EDT Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)

Registration No. 333-291832

Prospectus Supplement No. 4

(To Prospectus dated December 11, 2025)

Jupiter Neurosciences, Inc.

This prospectus supplement updates, amends and supplements the prospectus dated December 11, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-291832) and is being filed to update, amend and supplement the information included in the Prospectus with information contained in our Current Report on Form 8-K, which was filed with the Securities and Exchange Commission (the “SEC”) on May 21, 2026 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement. Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Shares of our common stock, par value $0.0001 per share (our “Common Stock”), are listed on The Nasdaq Stock Market, LLC under the symbol “JUNS.” On May 20, 2026, the closing price of our Common Stock was $0.2050 per share.

Investing in our securities involves risks that are described in the “Risk Factors” section of the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or this prospectus supplement or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is May 21, 2026.